European Commission vs Big Pharma, or profit vs access?
Drug Discovery World
MARCH 29, 2023
UMNs have been defined in the context of the draft as diseases where there’s a lack of good treatments, and which have a high burden 3. What of the increased possibilities for ‘replacement pharmacy compounding’ for weekly hospital supplies, and for routine manufacturing of cell and gene therapies without a marketing authorisation?
Let's personalize your content